BioCentury | Jun 6, 2020
Finance

Sale of up to 19 Woodford stakes chips away at firm’s remaining portfolio

Backers of a fund formerly managed by fallen star investor Neil Woodford are finally getting another chunk of their money back, albeit for pence on the pound. Link Fund Solutions Ltd. announced Friday that it...
BioCentury | Feb 10, 2020
Finance

Woodford pain continues as report suggests deal to sell private biotech stakes falls through

Private biotech companies held by funds formerly managed by Neil Woodford haven’t rid themselves of the debacle that led to the star British investor’s demise. According to a report in The Times that did not...
BioCentury | Oct 19, 2019
Finance

Woodford’s empire crumbles. U.K biotech stays standing

Perhaps the greatest sign of robustness of the U.K. biotech sector is that it barely budged on the news this week of Neil Woodford’s demise. Woodford’s struggles came to an acrimonious and swift end as...
BC Extra | Oct 15, 2019
Financial News

Woodford flagship fund implodes as star fund manager axed

Neil Woodford’s struggles have come to an acrimonious end as the once vaunted British investor has been removed as fund manager of his firm’s flagship fund, Woodford Equity Income Fund, which is to be shuttered...
BC Extra | Aug 14, 2019
Company News

Aug. 14 Company Quick Takes: Myriad plunges on sales concerns; plus AbbVie-Allergan, TB Alliance, Akari, Carmine

Myriad falls on sales forecast, GeneSight concerns  Myriad Genetics Inc. (NASDAQ:MYGN) tumbled $19.05 (43%) to $25.50 Wednesday, the day after the molecular diagnostics maker reported 4Q revenues of $215 million, below FactSet’s consensus of $222...
BC Extra | Apr 9, 2019
Company News

Fosun gains pair of cell therapies from ReNeuron

ReNeuron gained 51p (30%) to 222p on Tuesday after it granted a Fosun subsidiary exclusive rights to develop and commercialize its hRPC and CTX stem cell therapies in China. ReNeuron Group plc (LSE:RENE) will receive...
BC Innovations | Mar 22, 2019
Product Development

Regulating regeneration in Europe

As Europe rethinks its policies on regenerative medicine, the question is whether it can regain its footing in a competitive field it once led, given the in-built inconsistencies across the EU’s member states. Europe positioned...
BC Week In Review | Feb 22, 2019
Clinical News

ReNeuron's hRPC stem cells improve vision in first cohort of retinitis pigmentosa patients

ReNeuron Group plc (LSE:RENE) said a single subretinal implantation of its hRPC stem cells led significant improvements in visual acuity in three patients with retinitis pigmentosa in the first cohort of the Phase II portion...
BC Innovations | Oct 4, 2018
Emerging Company Profile

Banking on exosomes

Alxerion Biotech LLC is building a biobank of exosomes from diverse species as a comprehensive source for therapeutics discovery. Its initial focus is on cancer. The company aims to collect and screen 350,000 samples from...
BC Extra | Apr 10, 2018
Company News

Management tracks: Immunomedics, argenx

Antibody company Immunomedics Inc. (NASDAQ:IMMU) hired Robert Iannone as CMO and head of R&D. He was SVP and head of immuno-oncology, global medicines development at AstraZeneca plc (LSE:AZN; NYSE:AZN). Antibody company argenx S.E. (Euronext:ARGX; NASDAQ:ARGX)...
Items per page:
1 - 10 of 166
BioCentury | Jun 6, 2020
Finance

Sale of up to 19 Woodford stakes chips away at firm’s remaining portfolio

Backers of a fund formerly managed by fallen star investor Neil Woodford are finally getting another chunk of their money back, albeit for pence on the pound. Link Fund Solutions Ltd. announced Friday that it...
BioCentury | Feb 10, 2020
Finance

Woodford pain continues as report suggests deal to sell private biotech stakes falls through

Private biotech companies held by funds formerly managed by Neil Woodford haven’t rid themselves of the debacle that led to the star British investor’s demise. According to a report in The Times that did not...
BioCentury | Oct 19, 2019
Finance

Woodford’s empire crumbles. U.K biotech stays standing

Perhaps the greatest sign of robustness of the U.K. biotech sector is that it barely budged on the news this week of Neil Woodford’s demise. Woodford’s struggles came to an acrimonious and swift end as...
BC Extra | Oct 15, 2019
Financial News

Woodford flagship fund implodes as star fund manager axed

Neil Woodford’s struggles have come to an acrimonious end as the once vaunted British investor has been removed as fund manager of his firm’s flagship fund, Woodford Equity Income Fund, which is to be shuttered...
BC Extra | Aug 14, 2019
Company News

Aug. 14 Company Quick Takes: Myriad plunges on sales concerns; plus AbbVie-Allergan, TB Alliance, Akari, Carmine

Myriad falls on sales forecast, GeneSight concerns  Myriad Genetics Inc. (NASDAQ:MYGN) tumbled $19.05 (43%) to $25.50 Wednesday, the day after the molecular diagnostics maker reported 4Q revenues of $215 million, below FactSet’s consensus of $222...
BC Extra | Apr 9, 2019
Company News

Fosun gains pair of cell therapies from ReNeuron

ReNeuron gained 51p (30%) to 222p on Tuesday after it granted a Fosun subsidiary exclusive rights to develop and commercialize its hRPC and CTX stem cell therapies in China. ReNeuron Group plc (LSE:RENE) will receive...
BC Innovations | Mar 22, 2019
Product Development

Regulating regeneration in Europe

As Europe rethinks its policies on regenerative medicine, the question is whether it can regain its footing in a competitive field it once led, given the in-built inconsistencies across the EU’s member states. Europe positioned...
BC Week In Review | Feb 22, 2019
Clinical News

ReNeuron's hRPC stem cells improve vision in first cohort of retinitis pigmentosa patients

ReNeuron Group plc (LSE:RENE) said a single subretinal implantation of its hRPC stem cells led significant improvements in visual acuity in three patients with retinitis pigmentosa in the first cohort of the Phase II portion...
BC Innovations | Oct 4, 2018
Emerging Company Profile

Banking on exosomes

Alxerion Biotech LLC is building a biobank of exosomes from diverse species as a comprehensive source for therapeutics discovery. Its initial focus is on cancer. The company aims to collect and screen 350,000 samples from...
BC Extra | Apr 10, 2018
Company News

Management tracks: Immunomedics, argenx

Antibody company Immunomedics Inc. (NASDAQ:IMMU) hired Robert Iannone as CMO and head of R&D. He was SVP and head of immuno-oncology, global medicines development at AstraZeneca plc (LSE:AZN; NYSE:AZN). Antibody company argenx S.E. (Euronext:ARGX; NASDAQ:ARGX)...
Items per page:
1 - 10 of 166